Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$15.83 - $23.35 $1.99 Million - $2.93 Million
125,484 Added 381.41%
158,384 $3.25 Million
Q4 2023

Feb 14, 2024

BUY
$16.2 - $23.18 $532,980 - $762,622
32,900 New
32,900 $706,000
Q3 2022

Nov 14, 2022

SELL
$25.97 - $38.53 $149,405 - $221,663
-5,753 Reduced 15.83%
30,588 $939,000
Q2 2022

Aug 15, 2022

BUY
$20.88 - $35.19 $386,092 - $650,698
18,491 Added 103.59%
36,341 $1.07 Million
Q1 2022

May 16, 2022

BUY
$29.0 - $47.27 $517,650 - $843,769
17,850 New
17,850 $574,000
Q4 2021

Feb 14, 2022

SELL
$42.59 - $55.02 $647,368 - $836,304
-15,200 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$48.48 - $78.23 $507,391 - $818,755
10,466 Added 221.08%
15,200 $767,000
Q2 2021

Aug 16, 2021

SELL
$50.3 - $78.44 $881,809 - $1.38 Million
-17,531 Reduced 78.74%
4,734 $371,000
Q1 2021

May 17, 2021

BUY
$53.8 - $81.53 $244,897 - $371,124
4,552 Added 25.7%
22,265 $1.27 Million
Q4 2020

Feb 16, 2021

SELL
$36.89 - $93.56 $2 Million - $5.07 Million
-54,224 Reduced 75.38%
17,713 $1.48 Million
Q3 2020

Nov 16, 2020

BUY
$23.13 - $38.84 $313,110 - $525,777
13,537 Added 23.18%
71,937 $2.58 Million
Q2 2020

Aug 14, 2020

SELL
$16.01 - $28.82 $292,983 - $527,406
-18,300 Reduced 23.86%
58,400 $1.41 Million
Q1 2020

May 15, 2020

BUY
$14.2 - $27.98 $550,917 - $1.09 Million
38,797 Added 102.36%
76,700 $1.34 Million
Q4 2019

Feb 14, 2020

SELL
$14.4 - $19.99 $20,289 - $28,165
-1,409 Reduced 3.58%
37,903 $660,000
Q3 2019

Nov 14, 2019

BUY
$15.32 - $21.92 $430,369 - $615,776
28,092 Added 250.37%
39,312 $602,000
Q2 2019

Aug 14, 2019

BUY
$18.5 - $28.14 $207,570 - $315,730
11,220 New
11,220 $233,000

Others Institutions Holding DNLI

About Denali Therapeutics Inc.


  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $2.88B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track This Portfolio

Track Pdt Partners, LLC Portfolio

Follow Pdt Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pdt Partners, LLC with notifications on news.